# Akeso: Phase 3 study started recruiting, 900 planned (Gastric / Gastroesophageal Junction Adenocarcinoma)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Akeso |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma |
| NCT ID | NCT07700979 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Gastric / Gastroesophageal Junction Adenocarcinoma |
| Intervention types | drug |
| Target enrollment | 900 |
| Site countries | United States, China, Germany, Poland |
| Posted | 2026-07-14 |
| Planned start | 2026-09-24 |
| Event | Started recruiting |
| Event date | 2026-09-24 |
| Last update posted | 2026-09-29 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 900 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07700979). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.